Development of Hypocalcemia Due to Targeted Therapies

Creative Commons License

GÖKÇAY CANPOLAT A., Canlar S., Aydogan B. I., GÜLLÜ S., ERDOĞAN M. F.

TURKISH JOURNAL OF ENDOCRINOLOGY AND METABOLISM, cilt.24, sa.1, ss.105-108, 2020 (ESCI) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 24 Sayı: 1
  • Basım Tarihi: 2020
  • Doi Numarası: 10.25179/tjem.2019-70737
  • Dergi Adı: TURKISH JOURNAL OF ENDOCRINOLOGY AND METABOLISM
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, Academic Search Premier, CINAHL, EMBASE, Directory of Open Access Journals, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.105-108
  • Anahtar Kelimeler: Erlotinib, vandetanib, hypocalcemia, hypoparathyroidism, PARATHYROID HYPERPLASIA, TGF-ALPHA, EGFR, CANCER
  • Ankara Üniversitesi Adresli: Evet

Özet

Novel biological agents are available for the treatment of malignancies, and apart from their utility, they may also have several side effects. The effects on the endocrine system are frequently observed, among which thyroid dysfunctions are common and well-characterized, whereas parathyroid dysfunctions are rare and not well characterized. Herein, we describe two of our patients that displayed hypoparathyroidism and were treated with epidermal growth factor receptor (EGFR) inhibitor erlotinib, vascular endothelial growth factor receptor, and EGFR inhibitor vandetanib.